Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

Bone Marrow Transplantation

Volumn 34, Issue 6, 2004, Pages 511-514

  Anderlini, P ^a   Acholonu, S A ^a   Okoroji, G J ^a   Andersson, B S ^a   Couriel, D R ^a   De Lim, M J ^a   Donato, M L ^a   Khouri, I F ^a   Giralt, S A ^a   Ueno, N T ^a   Champlin, R E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic bone marrow transplantation; Donor leukocyte infusions; Donor lymphocyte infusions; Hodgkin's disease; Hodgkin's lymphoma

Indexed keywords

CD3 ANTIGEN; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LEUKOCYTE TRANSFUSION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, CD3; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HODGKIN DISEASE; HUMANS; LYMPHOCYTE TRANSFUSION; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 4644239491     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704621     Document Type: Article

References (14)

1. Collins RH, Shpilberg o, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
2. Baron F, Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 2000; 40: 468-476.
3. Porter DL, Collins RH, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
4. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
5. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
6. Peggs KP, Thomson K, Chopra R et al. Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: evidence of a therapeutically relevant graft-versus-lymphoma effect. Blood 2003; 102: 198a (abstr.).
7. Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with hematologic malignancies. J Clin Oncol 2002; 20: 4022-4031.
8. Porter DL, Luger SM, Duffy KM et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Bl Marrow Transplant 2001; 7: 230-238.
9. Anderlini P, Giralt S, Andersson B et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615-620.
10. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
11. Milpied N, Fielding AK, Pearce R, et al., for the European group for blood and marrow transplantation. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996; 14: 1291-1296.
12. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342-2350.
13. Robinson SP, Sureda A, Mackinnon S et al. Reduced intensity allogeneic stem cell transplantation for Hodgkin's disease: an analysis from the European Group for Blood and Marrow Transplantation. Blood 2002; 100: 144a (abstr.).
14. Akpek G, Ambinder RE, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314-4321.